{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Early+Stage&page=2", "query": { "condition": "Early Stage", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Early+Stage&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-25T19:52:31.037Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00308529", "title": "Irinotecan, Carboplatin, Bevacizumab, and Radiation Therapy in the Treatment of Limited Stage Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Small Cell Lung", "Lung Cancer" ], "interventions": [ { "name": "irinotecan", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "bevacizumab", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "SCRI Development Innovations, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2006-03", "completion_date": "2009-01", "has_results": false, "last_update_posted_date": "2010-06-22", "last_synced_at": "2026-06-25T19:52:31.037Z", "location_count": 4, "location_summary": "Fort Myers, Florida • Cincinnati, Ohio • Chattanooga, Tennessee + 1 more", "locations": [ { "city": "Fort Myers", "state": "Florida" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Chattanooga", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00308529" }, { "nct_id": "NCT03043794", "title": "Study of Stereotactic Radiotherapy for Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Stereotactic Body Radiation Therapy SBRT", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "100 Years", "sex": "FEMALE", "summary": "50 Years to 100 Years · Female only" }, "enrollment_count": 4, "start_date": "2017-08-01", "completion_date": "2023-10-22", "has_results": true, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-06-25T19:52:31.037Z", "location_count": 2, "location_summary": "Washington D.C., District of Columbia • Baltimore, Maryland", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03043794" }, { "nct_id": "NCT00000317", "title": "Early Phase II Trials for Cocaine Medication Development - 1", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cocaine-Related Disorders", "Substance-Related Disorders" ], "interventions": [ { "name": "Risperidone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Relapse prevention counseling", "type": "BEHAVIORAL" } ], "intervention_types": [ "DRUG", "BEHAVIORAL" ], "sponsor": "New York State Psychiatric Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 31, "start_date": "1996-08", "completion_date": "1999-07", "has_results": false, "last_update_posted_date": "2017-06-26", "last_synced_at": "2026-06-25T19:52:31.037Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000317" }, { "nct_id": "NCT02764762", "title": "Triple Combination Therapy in High Risk Crohn's Disease (CD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Crohn Disease" ], "interventions": [ { "name": "Vedolizumab", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 55, "start_date": "2017-04-18", "completion_date": "2022-07-05", "has_results": true, "last_update_posted_date": "2023-07-14", "last_synced_at": "2026-06-25T19:52:31.037Z", "location_count": 27, "location_summary": "Dothan, Alabama • Clearwater, Florida • Atlanta, Georgia + 24 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Clearwater", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Idaho Falls", "state": "Idaho" }, { "city": "Evanston", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02764762" }, { "nct_id": "NCT06976268", "title": "A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Parkinson Disease" ], "interventions": [ { "name": "BHV-8000", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biohaven Therapeutics Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "40 Years to 85 Years" }, "enrollment_count": 550, "start_date": "2025-05-28", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2026-01-14", "last_synced_at": "2026-06-25T19:52:31.037Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Los Angeles, California • Farmington, Connecticut + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Farmington", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Atlantis", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06976268" }, { "nct_id": "NCT04928976", "title": "Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Alzheimer Disease", "Preclinical Alzheimer's Disease", "Prodromal Alzheimer's Disease", "Alzheimer's Disease (Incl Subtypes)", "Mild Cognitive Impairment" ], "interventions": [], "intervention_types": [], "sponsor": "Novoic Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "50 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "50 Years to 85 Years" }, "enrollment_count": 67, "start_date": "2021-01-22", "completion_date": "2021-07-30", "has_results": false, "last_update_posted_date": "2021-09-05", "last_synced_at": "2026-06-25T19:52:31.037Z", "location_count": 1, "location_summary": "Santa Ana, California", "locations": [ { "city": "Santa Ana", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04928976" }, { "nct_id": "NCT06654050", "title": "Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Mesothelioma", "Malignant Mesothelioma (MM)", "Early-stage Mesothelioma", "Subclinical Mesothelioma", "BRCA1-Associated Protein-1 (BAP1) Mutations", "Early-stage BAP1-associated Malignancies" ], "interventions": [ { "name": "alrizomadlin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 0, "start_date": "2026-03-16", "completion_date": "2026-03-16", "has_results": false, "last_update_posted_date": "2026-03-17", "last_synced_at": "2026-06-25T19:52:31.037Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06654050" }, { "nct_id": "NCT02345824", "title": "Early-Phase Study to Assess Inhibitor Ribociclib in Patients With Recurrent Glioblastoma or Anaplastic Glioma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma", "Glioma" ], "interventions": [ { "name": "Ribociclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Virginia", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 3, "start_date": "2016-03", "completion_date": "2020-01", "has_results": false, "last_update_posted_date": "2018-06-07", "last_synced_at": "2026-06-25T19:52:31.037Z", "location_count": 1, "location_summary": "Charlottesville, Virginia", "locations": [ { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02345824" }, { "nct_id": "NCT04290897", "title": "Oxaloacetate for the Improvement of Cognitive Complaints in Stage 0-IIIA Breast Cancer Survivors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anatomic Stage 0 Breast Cancer AJCC v8", "Anatomic Stage I Breast Cancer AJCC v8", "Anatomic Stage IA Breast Cancer AJCC v8", "Anatomic Stage IB Breast Cancer AJCC v8", "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage IIA Breast Cancer AJCC v8", "Anatomic Stage IIB Breast Cancer AJCC v8", "Anatomic Stage IIIA Breast Cancer AJCC v8", "Early-Stage Breast Carcinoma", "Prognostic Stage 0 Breast Cancer AJCC v8", "Prognostic Stage I Breast Cancer AJCC v8", "Prognostic Stage IA Breast Cancer AJCC v8", "Prognostic Stage IB Breast Cancer AJCC v8", "Prognostic Stage II Breast Cancer AJCC v8", "Prognostic Stage IIA Breast Cancer AJCC v8", "Prognostic Stage IIB Breast Cancer AJCC v8", "Prognostic Stage IIIA Breast Cancer AJCC v8" ], "interventions": [ { "name": "Anhydrous Enol-oxaloacetate", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "74 Years", "sex": "FEMALE", "summary": "18 Years to 74 Years · Female only" }, "enrollment_count": 18, "start_date": "2021-09-29", "completion_date": "2024-11-12", "has_results": false, "last_update_posted_date": "2025-07-15", "last_synced_at": "2026-06-25T19:52:31.037Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04290897" }, { "nct_id": "NCT04713475", "title": "Study of Safety, Tolerability and Efficacy of PBGM01 in Pediatric Participants With GM1 Gangliosidosis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "GM1 Gangliosidosis", "GM1 Gangliosidosis, Type I", "GM1 Gangliosidosis, Type 2", "Beta-Galactosidase-1 (GLB1) Deficiency" ], "interventions": [ { "name": "PBGM01", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Gemma Biotherapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Month", "maximum_age": "24 Months", "sex": "ALL", "summary": "1 Month to 24 Months" }, "enrollment_count": 26, "start_date": "2021-03-17", "completion_date": "2029-02", "has_results": false, "last_update_posted_date": "2025-05-21", "last_synced_at": "2026-06-25T19:52:31.037Z", "location_count": 4, "location_summary": "Oakland, California • Minneapolis, Minnesota • New Brunswick, New Jersey + 1 more", "locations": [ { "city": "Oakland", "state": "California" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04713475" } ] }